Press Releases

--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109’s potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-- --Topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative
Read More
KB109 demonstrated favorable safety and tolerability profile Kaleido intends to file an Investigational New Drug (IND) application, with the goal of advancing KB109 directly into a pivotal registration program Company to host conference call today at 8:30am ET LEXINGTON, Mass., March 24, 2021
Read More
Displaying 1 - 10 of 14
Print Page
Email Alerts
Investor Contact